Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Defy Medical vs NuuVim

Defy Medical
Graded #325

Lower grade

vs+8
NuuVim
Graded #153

Higher grade

The verdict

NuuVim takes it — 68.2/100 to 60.2/100.

NuuVim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNuuVim +43
45
88
Dose & formulationNuuVim +40
56
96
Clinical oversightDefy Medical +38
80
42
Labs & monitoringDefy Medical +15
65
50
FulfillmentDefy Medical +2
63
61
Contract termsDefy Medical +8
55
47
Defy Medical · left barNuuVim · right bar

The numbers

MetricDefy MedicalNuuVim
WeighScore60.2/10068.2/100
GradeCC
Scorecard rank#325#153
SemaglutideNot disclosed$79/mo (all doses, 3-mo plan, new patients only, compounded)
TirzepatideNot disclosed$133/mo (all doses, 3-mo plan, new patients only, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesYes
Defy Medical

Graded #325 · C

Strengths

  • Multiple GLP-1 options: semaglutide, tirzepatide, liraglutide
  • Offers injection, ODT, and oral drop delivery forms
  • Comprehensive blood testing and named medical director
  • Established clinic with strong Trustpilot review volume

Where it loses points

  • GLP-1 pricing not published on the website
  • States served and shipping limits not disclosed
  • Compounded versus brand status not stated online
  • Lab-heavy, consult-first model may cost more upfront
NuuVim

Graded #153 · C

Strengths

  • Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
  • Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
  • LegitScript Certified and HIPAA-compliant
  • Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
  • Operating legal entity disclosed: NuuVim LLC, Texas governing law

Where it loses points

  • There is no month-to-month plan: every rate is billed as one three-month payment
  • The advertised $79 and $133 are introductory rates for customers new to GLP-1s; on renewal they become $133 and $199.67
  • The site's own llms.txt advertises pricing, FAQ and terms files that all 404
  • No state count is published
  • FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard